As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
A research agenda focusing on breakthrough infections, reinfections,
severity, and sequelae is needed to inform clinical practice when
COVID-19 emphasis shifts from eradication to living with the disease.